Article
Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma.
JAAPA : official journal of the American Academy of Physician Assistants - 1 May 2018
Buckley Breea, Pierce Bradley
Abstract excerpt
This article describes the use of vemurafenib, a BRAF inhibitor, to achieve disease regression in a woman with extensive metastatic melanoma and the BRAF V600 gene mutation. Given the improved survival rates seen in these patients, clinicians need to be aware of long-term patient management and adverse reactions to the drug.
Topics
Join the communities discussing this publication.